AFMD

Affimed N.V.

7.11 USD
+0.01 (+0.14%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Affimed N.V. stock is up 35.43% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30% of the previous 9 June’s closed higher than May. In the last 2 Unusual Options Trades, there were 2 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
03 Jun 16:37 21 Jun, 2024 7.50 CALL 200 504
12 Jun 18:57 19 Jul, 2024 7.50 CALL 4845 311

About Affimed N.V.

Affimed N.V. focuses on discovering and developing cancer immunotherapies. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers.

  • Laidlaw & Co.
    Thu Jun 13, 10:22
    buy
    confirm
  • HC Wainwright & Co.
    Thu Jun 13, 06:16
    buy
    confirm
  • HC Wainwright & Co.
    Mon Jun 3, 07:27
    buy
    confirm